Apellis Stock Rises on $300M Royalty Deal With Sobi for Aspaveli

Key Takeaways APLS stock rose 3.2% on a $300M capped royalty deal with Sobi for ex-U.S. sales of Aspaveli. Apellis retains U.S. rights to Empaveli and gains near-term cash plus a potential $25M in milestone payments. FDA and EU reviews are underway for the label expansion of pegcetacoplan for two rare kidney diseases.Apellis Pharmaceuticals’ (APLS) shares gained 3.2% on Tuesday following the announcement of a capped royalty deal with Sobi, under which Apellis will receive up to $300 million in return for ...